SPARC share price tumbles 20% as Sun Pharma's arm halts development of Psoriasis drug
SPARC share price: Shares of Sun Pharma Advanced Research Company (SPARC), the research division of India's top pharmaceutical firm Sun Pharma, fell by 20% on Wednesday after unsatisfactory results from Phase 2 trials of its experimental drug SCD-044. SPARC share price opened at an intraday high of ₹ 186 apiece on the BSE, the stock touched an intraday low of ₹ 156.50 per share.
SCD-044, referred to as Vibozilimod, was being developed for the treatment of psoriasis and atopic dermatitis. Nevertheless, the company announced that the drug did not achieve the primary endpoints in both of its clinical trials. Consequently, SPARC declared that it will halt further clinical development for SCD-044.
Both Sun Pharma and SPARC will now evaluate the future direction of this compound.
This development represents a setback, as SCD-044 was viewed as one of the more promising candidates in SPARC's specialty pipeline. In a filing with the exchange, the company noted that neither the SOLARES PsO trial nor the SOLARES AD trial achieved their primary endpoints—defined as a 75 percent reduction in PASI (Psoriasis Area and Severity Index) or EASI (Eczema Area and Severity Index) scores by Week 16.
SPARC, a biopharmaceutical subsidiary of Sun Pharma that focuses on research, aims to drive innovation in fields such as oncology, neurodegenerative diseases, and inflammatory disorders.
In the fourth quarter of fiscal year 2025 (Q4FY25), SPARC announced a total income of ₹ 20.96 crore, marking a 38.8% increase from ₹ 15.10 crore in the third quarter (Q3FY25).
However, the loss before tax increased to ₹ 105.41 crore compared to ₹ 79.44 crore in the prior quarter, indicating a 32.7% decline in profitability. The total expenses for the quarter rose by 33.7%, reaching ₹ 126.37 crore, up from ₹ 94.54 crore in Q3.
Anshul Jain, Head of Research at Lakshmishree Investments, SPARC share price has gapped down, breaching its rising moving averages, indicating a clear structure shift from bullish to bearish. After a sharp 76.88% correction in 47 weeks, the stock was attempting to form a higher low on the weekly chart, which now appears to have failed following the negative clinical trial news. With sentiment turning weak, immediate support is placed at ₹ 128. A breach of this support may accelerate further downside in the short term.
Disclaimer: The views and recommendations made above are those of individual analysts or broking companies, and not of Mint. We advise investors to check with certified experts before making any investment decisions.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hindu
2 hours ago
- The Hindu
Newborn screening, early treatment can cut sickle cell anaemia mortality: ICMR study
Post-birth diagnosis resulting in early treatment can substantially improve the quality of life and reduce mortality in patients with sickle cell disease to less than five per cent from the reported 20-30 per cent, according to an ICMR study. As many as 63,536 newborns were tested over a five year period from 2019- 2024 as part of the study on Newborn Screening for Sickle cell Disease conducted by the National Institute of Immunohaematology in Mumbai under the India Council of Medical Research (ICMR) across seven centres in high prevalence areas of India. The study is yet to be published. The newborn screening program helps find out if a baby is born with Sickle Cell Disease (SCD), a serious inherited blood disorder, soon after birth, explained Manisha Madkaikar, director of ICMR- Centre for Research Management and Control of Haemoglobinopathies (CRHCM) in Nagpur. "If not detected early, this disease can cause life-threatening problems like severe infections, anaemia (low blood levels), and even strokes in infants," she stressed. "Finding the disease early can save lives by allowing doctors to start treatment before problems begin," Prabhakar Kedar, Scientist F, ICMR-NIIH , who is the principal investigator of the study, said. Babies diagnosed early can be given preventive antibiotics (like penicillin) to avoid infections and get regular checkups and care from specialists, Dr Madkaikar said. Early detection also helps in getting important vaccines to protect against serious illnesses while parents can also be taught the signs of danger so they can act quickly. It also helps families and doctors plan long-term treatment, provides genetic counselling to the family, and increases awareness, reducing the number of future cases, Dr Madkaikar explained. This screening is especially important in tribal and high-risk areas of India, where many cases go undiagnosed, leading to early childhood deaths, Dr Kedar highlighted. "With screening, many of these deaths can be prevented," he said. During the study, 7,275 babies (11.4 per cent) were found to be carriers of the sickle cell gene. This means they don't have the disease but can pass it on to their children, Dr Kedar said, adding, 569 babies (0.9 per cent) were found to have SCD. These babies were followed up for the confirmation of diagnosis, parents were counselled about SCD, preventive measures to be taken for or to avoid complications, and informed about prenatal diagnosis to avoid any further births of affected children in the family. "The babies were given comprehensive care, including penicillin prophylaxis, folic acid supplementation, appropriate vaccinations and hydroxyurea therapy, as indicated. This resulted in reduction in mortality in these children to less than 5 per cent from the earlier reported mortality of 20-30 per cent," Dr Kedar said. This study shows that newborn screening works and can save lives, especially in places with a high number of cases like tribal areas, Dr Kedar said. This study was coordinated by Harpreet Kaur, senior scientists at ICMR, Delhi. "By detecting Sickle Cell Disease early, babies can get timely care, live healthier lives, and families can be better prepared," Dr Kedar said. The seven centres which participated in the study are National Institute For Implementation Research on Non-Communicable Diseases in Jodhpur, Society for Education, Welfare and Action-Rural (SEWA -Rural) in Gujarat, the Nilgiris Adivasi Welfare Association (NAWA), Tamil Nadu, ICMR- National Institute for Research in Reproductive Health in Mumbai, ICMR-National Institute of Research in Tribal Health (NIRTH) in Jabalpur, ICMR-Regional Medical Research Centre, Bhubaneswar and ICMR- Centre for Research Management and Control of Haemoglobinopathies (CRHCM) in Chandrapur. Of the total 63,536 newborns tested, 57 per cent belonged to tribal parents and rest from others, Dr Kedar informed. The aim of the study was also to understand the regional variability and role of genetic modifiers in sickle cell disease as well as to identify barriers for newborn screening implementation, he explained.
Mint
4 hours ago
- Mint
Zee Media share price in focus after promoter group buys 1.11 crore shares. Do you own?
Zee Media share price will remain in focus on Monday after promoter group acquired significant stake in the company. On Friday, the media company stock fell over 1.85 per cent in the early trading hours to ₹ 13.25, however, recovered quickly surging to ₹ 13.47 per share. The stock finally closed at ₹ 13.42. According to reports, AUV Innovations LLP, part of the promoter group, has made a notable acquisition in Zee Media Corporation Limited by acquiring 1,11,00,000 shares at an average price of ₹ 13.6 through open market transactions. The transaction was total valued at ₹ 1,504 lakhs. This comes after earlier purchases in May 2025, when AUV Innovations LLP acquired 2,40,000 shares on May 16, followed by another 29,60,000 shares on May 19. In total, the promoter has accumulated 1.43 crore shares through these open market transactions. Zee Media Corporation Limited declared its financial results for the January–March quarter on May 5, 2025. As per the consolidated financial statements, the company's net loss for the fourth quarter of FY 2024–25 surged by 464% year-on-year (YoY) to ₹ 36.76 crore, compared to ₹ 6.51 crore reported during the same period last year. The media company reported a 13% decline in its core operational revenue, which fell to ₹ 155.80 crore in the January–March quarter of FY 2024–25, down from ₹ 178.98 crore in the corresponding quarter last year. Meanwhile, Zee Media's total expenses for the fourth quarter rose by 6.39% year-on-year to ₹ 200.21 crore, compared to ₹ 188.17 crore in the same period of the previous fiscal. 'The Group has incurred a loss of Rs. 11,942 lakhs during the year ended 31 March, 2025 and the Working Capital stands negative as at that date. To address he same, the Group has been taking various steps including cost rationalization measures and has obtained credit period extension to discharge some of its contractual obligations,' said Zee Media Corp in the BSE filing. Disclaimer: This story is for educational purposes only. The views and recommendations above are those of individual analysts or broking companies, not Mint. We advise investors to check with certified experts before making any investment decisions.
Time of India
4 hours ago
- Time of India
Waaree Energies shares may break April 2025 peak after Friday's 12% jump: Anand James
After a blistering 12% rally on Friday, Waaree Energies is back in the spotlight. With the stock inching closer to its April 2025 peak, Anand James of Geojit believes this breakout attempt may finally stick, setting the stage for fresh highs. Edited excerpts from a chat with Anand James, Chief Market Strategist, Geojit Investments Limited on trading strategy for the week ahead: by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Bank Owned Properties For Sale In Bayugan (Prices May Surprise You) Foreclosed Homes | Search ads Search Now Undo Nifty has been struggling to move sustainably higher than the 25,000-mark for the last few weeks, as visible this time again. On the fundamental side, triggers are missing, but why is 25k such an important level to watch out for on the charts? Yes, 25k is indeed a daunting challenge. Previous attempts to clear the same had proved to be short-lived as there was hardly any follow-through momentum, thus leading to a sharp withdrawal. Hence, the reapproach of the 25k mount is accompanied by concerns about sustainability. Being at the upper Bollinger band as well, it would require further momentum to continue the uptrend. ADX at 13.2 does not indicate strong momentum either. Nevertheless, upswing attempts may be seen initially, but may not clear the 25200-460 band. Alternatively, inability to float above 25045 could see dips, but will wait for 24865 to switch sides. Give us your trading strategy for Nifty monthly expiry next week. What are the levels to watch out for? We would be entering the expiry week with a surprise jump above 25000, that has attracted call OTM buyers only as far as 25500. The same pattern is visible in the 3rd July expiry contract as well with PE buying accumulated at 24800. This raises the expectation of a trading range limited to the 25500-24800 region, calling for a short strangle option strategy with these at the strikes for the two legs. An alternative approach would be to short straddle at 25000, with stop loss placed at 25500 and 24800 on either side. Live Events With BSE and NSE swapping their expiry days with effect from September, how would your trading strategy change when it comes to index options? Monday is now sandwiched between the weekend and expiry, elevating the caution that is usually commanded by day. Even though Monday has to deal with weekend news flows, there is always an optimism, being the start of the week. But with expiry falling on Tuesday, such vibes will be restrained. This would mean that premium expansion and directional entry-exits will be largely front loaded, as there will be little opportunity to escape from theta decay post Thursday, with Friday being the weekend eve and Monday being the expiry eve. For derivative traders, Thursday has been associated with Nifty expiry day for many years. Now with Sensex coming in on Thursday, how do you see trader interest evolving in Sensex contracts? Since late 2023, Sensex F&O has seen a steady increase in trading volume. Between March and December 2024, it consistently accounted for about 70% of the total trading volume across both the NSE and BSE. This momentum accelerated further in January 2025, when the Sensex saw a 12% month-on-month volume spike, coinciding with its shift in weekly expiry from Friday to Tuesday. Now, a new phase of expiry restructuring is set to reshape this dynamic. From September 2025, the Nifty will move its expiry to Tuesday, while the Sensex will shift to Thursday. This change could significantly alter the volume patterns across the two exchanges. Nifty may reclaim lost ground with Tuesday expiries, attracting traders looking to capitalize on early-week strategies and weekend time decay. This could lead to increased activity on Mondays and Tuesdays. Meanwhile, with Thursday as the new expiry, Sensex will see shorter positioning windows earlier in the week, which may temper the intense volume surges, especially on the expiry day. That said, the new trading dynamics will take a while to play out, and it is also possible that Sensex will get more opportunities to price the events of the week, having more trading days ahead of expiry. Time will tell. The broader market underperformed this week. Are the charts hinting at a revival in small and midcaps? The weakness in the small and mid-caps was visible throughout the week. On Thursday, when Nifty closed almost flat, the small cap 250 index fell nearly 2%. And on Friday, when Nifty rose 1.29%, small cap 250 index rose only 0.6%. Friday's optimistic rise has not managed to retrace even 50% of Thursday's fall, raising fears of an extended fall to 16650-16500. Alternatively, a rise above 16900 will help shrug off the weakness, but we feel that upsides may be limited. Waaree Energies surprised investors on Friday with a sharp 12% jump. How to trade the stock on Monday? An outright jump from one end to the other end of the Bollinger will render the stock unattractive to jump into right away. But we feel that the April 2025 peak, which the stock has attempted several times unsuccessfully, will be broken in this attempt. Longs entered on dips to 2895 may have stop loss placed below 2822. Give us your top ideas for the week ahead VIPIND (CMP: 409) Target – 450 Stoploss – 399 The stock recently confirmed a breakout from an inverted Head & Shoulders pattern and continues to maintain its upward momentum. On the monthly chart, the SMIO histogram has crossed above the zero line, suggesting a shift in long-term sentiment. Additionally, the RSI is holding near 60, indicating sustained strength without being overbought. On the daily timeframe, the appearance of an inverted hammer—a classic bullish reversal signal following a dip—adds further conviction to the upside potential. Based on this technical setup, the stock is expected to move toward the 450 mark in the near term. To manage risk, a stop-loss should be placed just below ₹399.
